AMG-714 clinical trials
Also written AMG 714 and PRV-015.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2002
How each study uses AMG-714 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2007 | 1 |
| 2016 | 2 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Amgen (4) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Provention Bio, a Sanofi Company (1)
Studies
Open first, then newest update. How each study uses AMG-714 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Evaluation of AMG 714 for VitiligoCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04338581Written as AMG 714How we know
- PRV-015 in Gluten-free Diet Non-responsive Celiac DiseaseCompletedPhase 2Provention Bio, a Sanofi CompanyNCT04424927Written as PRV-015How we know
- Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac DiseaseCompletedPhase 2AmgenNCT02633020Written as AMG 714How we know
- A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac DiseaseCompletedPhase 2AmgenNCT02637141Written as AMG 714How we know
- AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis SubjectsCompletedPhase 2AmgenNCT00443326Written as AMG 714How we know
- Phase 2 AMG 714 in Rheumatoid ArthritisCompletedPhase 2AmgenNCT00433875Written as AMG 714How we know
Codes
What other systems call AMG-714 · ClinicalTrials.gg INT001326
- MeSH (NLM) C000706949AMG-714One source NLM
- UNII (FDA) EJ48MR05C3ORDESEKIMABConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000706949 | AMG-714 | One source NLM |
| UNII (FDA) | EJ48MR05C3 | ORDESEKIMAB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.